Normi D. Gajjar

Normi D. Gajjar

Auto-generated profile, based on publicly available information

Normi D. Gajjar

Gujarat Technological University, Ahmedabad, India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2021 in European Journal of Medicinal Chemistry Reports
Verified
Journal Article
Open access
Vivek P. ChavdaVivek P. Chavda
Vivek P. Chavda
NGNormi Gajjar
Normi Gajjar
NSNirav Shah
Nirav Shah
DDDivyang J. Dave
Divyang J. Dave
Antivirals already on the market and expertise gained from the SARS and MERS outbreaks are gaining momentum as the most effective way to combat the coronavirus outbreak. SARS-CoV-2 has caused considerable mortality due to respiratory failure, highlighting the immediate need for successful therapies as well as the long-term need for antivirals to combat potential emergent mutants of coronaviruses. There are constant viral mutations are being observed due to which world is experiencing different waves of SARS-CoV-2. If our understanding of the virology and clinical presentation of COVID-19 grows, so does the pool of possible pharmacological targets. In COVID-19, the difficulties of proper analysis of current pre-clinical/clinical data as well as the creation of new evidence concerning drug repurposing will be crucial. The current manuscript aims to evaluate the repurposing of an anti-HIV drug Darunavir Ethanolate in COVID-19 treatment with in silico study and we discuss the therapeutic progress of Darunavir Etanolate, to prevent SARS-CoV-2 replication, which supports its clinical assessment for COVID-19 therapy.

31 May 2023 in 3 Biotech
Verified
Journal Article
Closed access
PDF file
UVUdayakumar Girdharlal Vegad
Udayakumar Girdharlal Vegad
NGNormi D. Gajjar
Normi D. Gajjar
PNPrinsa R. Nagar
Prinsa R. Nagar
SCSanjay P. Chauhan
Sanjay P. Chauhan
DPDevang J. Pandya
Devang J. Pandya
TDTejas Dhameliya
Tejas Dhameliya

26 July 2022 in ChemistrySelect
Verified
Journal Article
Closed access
DSDipen K. Sureja
Dipen K. Sureja
ASAshish P. Shah
Ashish P. Shah
NGNormi D. Gajjar
Normi D. Gajjar
SJShwetaba B. Jadeja
Shwetaba B. Jadeja
KBKunjan Bharatkumar Bodiwala
Kunjan Bharatkumar Bodiwala
TDTejas Dhameliya
Tejas Dhameliya

8 July 2022 in ChemistrySelect
Verified
Journal Article
Closed access
KBKaushikkumar A. Bhakhar
Kaushikkumar A. Bhakhar
PVPunit V. Vaghela
Punit V. Vaghela
SVSaiprasad D. Varakala
Saiprasad D. Varakala
SCShrdhhaba J. Chudasma
Shrdhhaba J. Chudasma
NGNormi D. Gajjar
Normi D. Gajjar
TDTejas M. Dhameliya
Tejas M. Dhameliya

9 October 2026 in Discover Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
APAnil Kumar Prajapati
Anil Kumar Prajapati
GSGaurang Shah
Gaurang Shah
NGNormi Gajjar
Normi Gajjar
Purpose Cardiac hypertrophy is a key contributor to adverse remodeling and the progression of cardiovascular diseases. Ponatinib, a multi-targeted tyrosine kinase inhibitor approved for oncology, has been shown to inhibit growth factor signaling pathways implicated in hypertrophy. This study aimed to investigate the molecular targets of Ponatinib and evaluate its effects on cardiac hypertrophy. Methods Network pharmacology was used to identify Ponatinib-associated targets and their overlap with cardiac disease-related genes. Protein–protein interaction (PPI) analysis, Gene Ontology (GO) analysis, and KEGG pathway enrichment analysis were performed to identify key pathways. Molecular docking assessed binding affinities with selected targets. In vitro validation was conducted in H9C2 (2–1) cells subjected to high-salt-induced hypertrophy, in which cell viability, cell size, and α-smooth muscle actin (α-SMA) levels were measured. Results Twenty-four overlapping targets were identified, with EGFR, MAPK8, MAP3K7, JAK2, and PDGFRB as key regulators enriched in MAPK and PI3K-Akt pathways. Docking showed strong binding affinities, particularly with PDGFRB and JAK2. In vitro, Ponatinib (0.25 µM) significantly reduced cardiomyocyte hypertrophy while maintaining cell viability. However, no significant reduction in α-SMA levels was observed. Conclusion Ponatinib attenuates cardiac hypertrophy through multi-target modulation of growth factor signaling pathways. Further studies are needed to explore its role in cardiac hypertrophy.